Does the media prefer ENTA or XNCR?

In the previous week, Xencor had 15 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 17 mentions for Xencor and 2 mentions for Enanta Pharmaceuticals. Xencor's average media sentiment score of 0.52 beat Enanta Pharmaceuticals' score of 0.34 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NNNN or ENTA?

Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 47.64%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has better valuation & earnings, NNNN or ENTA?

Anbio Biotechnology has higher earnings, but lower revenue than Enanta Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 171.84 $6.40M N/A N/A Enanta Pharmaceuticals $65.32M 6.12 -$81.89M -$2.59 N/A

Does the media prefer PAHC or ENTA?

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 2 mentions for Enanta Pharmaceuticals and 1 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.18 beat Enanta Pharmaceuticals' score of 0.34 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ENTA or XERS?

In the previous week, Xeris Biopharma had 22 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 24 mentions for Xeris Biopharma and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.34 beat Xeris Biopharma's score of -0.07 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xeris Biopharma 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Enanta Pharmaceuticals (ENTA) Competitors

$13.80 +0.03 (+0.21%)

As of 12:23 PM Eastern

Compare

ENTA vs. XNCR, NNNN, MLTX, PAHC, and XERS

Should you buy Enanta Pharmaceuticals stock or one of its competitors? MarketBeat compares Enanta Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enanta Pharmaceuticals include Xencor (XNCR), Anbio Biotechnology (NNNN), MoonLake Immunotherapeutics (MLTX), Phibro Animal Health (PAHC), and Xeris Biopharma (XERS).

How does Enanta Pharmaceuticals compare to Xencor?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Xencor (NASDAQ:XNCR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Enanta Pharmaceuticals has a net margin of -89.56% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Xencor	-155.59%	-28.66%	-20.38%

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Enanta Pharmaceuticals presently has a consensus target price of $20.29, indicating a potential upside of 47.64%. Xencor has a consensus target price of $24.86, indicating a potential upside of 18.01%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Enanta Pharmaceuticals is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Xencor had 15 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 17 mentions for Xencor and 2 mentions for Enanta Pharmaceuticals. Xencor's average media sentiment score of 0.52 beat Enanta Pharmaceuticals' score of 0.34 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Enanta Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Xencor has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Enanta Pharmaceuticals has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.12	-$81.89M	-$2.59	N/A
Xencor	$125.58M	12.47	-$91.92M	-$2.17	N/A

Summary

Enanta Pharmaceuticals beats Xencor on 10 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 47.64%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Anbio Biotechnology has a beta of 5.4, indicating that its stock price is 440% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Anbio Biotechnology has higher earnings, but lower revenue than Enanta Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	171.84	$6.40M	N/A	N/A
Enanta Pharmaceuticals	$65.32M	6.12	-$81.89M	-$2.59	N/A

Anbio Biotechnology has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Anbio Biotechnology's return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than Anbio Biotechnology. MarketBeat recorded 2 mentions for Enanta Pharmaceuticals and 0 mentions for Anbio Biotechnology. Enanta Pharmaceuticals' average media sentiment score of 0.34 beat Anbio Biotechnology's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Anbio Biotechnology	Neutral
Enanta Pharmaceuticals	Neutral

Summary

Enanta Pharmaceuticals beats Anbio Biotechnology on 8 of the 14 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to MoonLake Immunotherapeutics?

Enanta Pharmaceuticals (NASDAQ:ENTA) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Enanta Pharmaceuticals has higher revenue and earnings than MoonLake Immunotherapeutics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.12	-$81.89M	-$2.59	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Enanta Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -64.04% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Enanta Pharmaceuticals currently has a consensus target price of $20.29, suggesting a potential upside of 47.64%. MoonLake Immunotherapeutics has a consensus target price of $24.21, suggesting a potential upside of 40.41%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Enanta Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

In the previous week, MoonLake Immunotherapeutics had 12 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 14 mentions for MoonLake Immunotherapeutics and 2 mentions for Enanta Pharmaceuticals. MoonLake Immunotherapeutics' average media sentiment score of 0.59 beat Enanta Pharmaceuticals' score of 0.34 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MoonLake Immunotherapeutics	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Enanta Pharmaceuticals beats MoonLake Immunotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Phibro Animal Health currently has a consensus price target of $42.50, indicating a potential upside of 24.71%. Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 47.64%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Phibro Animal Health has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	1.07	$48.26M	$2.33	14.63
Enanta Pharmaceuticals	$65.32M	6.12	-$81.89M	-$2.59	N/A

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 2 mentions for Enanta Pharmaceuticals and 1 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.18 beat Enanta Pharmaceuticals' score of 0.34 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enanta Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phibro Animal Health has a net margin of 6.35% compared to Enanta Pharmaceuticals' net margin of -89.56%. Phibro Animal Health's return on equity of 37.14% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Summary

Phibro Animal Health beats Enanta Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Xeris Biopharma?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Xeris Biopharma (NASDAQ:XERS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Enanta Pharmaceuticals currently has a consensus target price of $20.29, suggesting a potential upside of 47.64%. Xeris Biopharma has a consensus target price of $10.80, suggesting a potential upside of 34.41%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Xeris Biopharma	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Enanta Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Xeris Biopharma has higher revenue and earnings than Enanta Pharmaceuticals. Xeris Biopharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.12	-$81.89M	-$2.59	N/A
Xeris Biopharma	$291.85M	4.75	$550K	-$0.11	N/A

In the previous week, Xeris Biopharma had 22 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 24 mentions for Xeris Biopharma and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.34 beat Xeris Biopharma's score of -0.07 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xeris Biopharma	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xeris Biopharma has a net margin of -5.12% compared to Enanta Pharmaceuticals' net margin of -89.56%. Xeris Biopharma's return on equity of 158.10% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Xeris Biopharma	-5.12%	158.10%	3.57%

Summary

Enanta Pharmaceuticals beats Xeris Biopharma on 9 of the 16 factors compared between the two stocks.

Get Enanta Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTA vs. The Competition

Export

Metric	Enanta Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$399.56M	$11.91B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-5.30	788.49	269.93	24.86
Price / Sales	6.12	968.58	650.62	108.28
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	4.53	10.34	11.25	6.44
Net Income	-$81.89M	$2.77B	$3.45B	$347.39M
7 Day Performance	6.10%	2.18%	3.67%	2.69%
1 Month Performance	0.29%	-1.35%	-0.49%	-0.90%
1 Year Performance	99.13%	191.22%	77.44%	23.51%

Enanta Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTA Enanta Pharmaceuticals	2.3181 of 5 stars	$13.80 +0.2%	$20.29 +47.0%	+99.6%	$400.72M	$65.32M	N/A	160	News Coverage
XNCR Xencor	2.2653 of 5 stars	$19.97 +0.6%	$24.25 +21.4%	+187.8%	$1.47B	$125.58M	N/A	280	Earnings Report Analyst Upgrade
NNNN Anbio Biotechnology	N/A	$10.15 -0.3%	N/A	N/A	$1.46B	$8.65M	N/A	27
MLTX MoonLake Immunotherapeutics	3.5688 of 5 stars	$18.71 -5.9%	$24.21 +29.4%	-65.2%	$1.46B	N/A	N/A	2	Trending News Earnings Report Options Volume
PAHC Phibro Animal Health	4.8401 of 5 stars	$36.37 +3.2%	$42.50 +16.9%	+22.0%	$1.43B	$1.30B	12.03	2,475	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. XNCR, NNNN, MLTX, PAHC, and XERS

How does Enanta Pharmaceuticals compare to Xencor?

Summary

How does Enanta Pharmaceuticals compare to Anbio Biotechnology?

Summary

How does Enanta Pharmaceuticals compare to MoonLake Immunotherapeutics?

Summary

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Summary

How does Enanta Pharmaceuticals compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. XNCR, NNNN, MLTX, PAHC, and XERS

How does Enanta Pharmaceuticals compare to Xencor?

Is ENTA or XNCR more profitable?

Do institutionals & insiders believe in ENTA or XNCR?

Do analysts prefer ENTA or XNCR?

Does the media prefer ENTA or XNCR?

Which has more risk and volatility, ENTA or XNCR?

Which has stronger valuation and earnings, ENTA or XNCR?

Summary

How does Enanta Pharmaceuticals compare to Anbio Biotechnology?

Do analysts rate NNNN or ENTA?

Which has more risk and volatility, NNNN or ENTA?

Which has better valuation & earnings, NNNN or ENTA?

Is NNNN or ENTA more profitable?

Do institutionals and insiders hold more shares of NNNN or ENTA?

Does the media prefer NNNN or ENTA?

Summary

How does Enanta Pharmaceuticals compare to MoonLake Immunotherapeutics?

Which has better valuation & earnings, ENTA or MLTX?

Which has more risk & volatility, ENTA or MLTX?

Is ENTA or MLTX more profitable?

Do analysts rate ENTA or MLTX?

Does the media refer more to ENTA or MLTX?

Do institutionals & insiders hold more shares of ENTA or MLTX?

Summary

How does Enanta Pharmaceuticals compare to Phibro Animal Health?

Which has more volatility & risk, PAHC or ENTA?

Do analysts prefer PAHC or ENTA?

Which has stronger valuation & earnings, PAHC or ENTA?

Do insiders and institutionals have more ownership in PAHC or ENTA?

Does the media prefer PAHC or ENTA?

Is PAHC or ENTA more profitable?

Summary

How does Enanta Pharmaceuticals compare to Xeris Biopharma?

Do analysts rate ENTA or XERS?

Do insiders and institutionals have more ownership in ENTA or XERS?

Which has more risk & volatility, ENTA or XERS?

Which has higher earnings and valuation, ENTA or XERS?

Does the media favor ENTA or XERS?

Is ENTA or XERS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools